Newsroom

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: SAMSON ROCK CAPITAL LLP (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named....

NEW YORK--(BUSINESS WIRE)--New eClerx research: 78% of marketing leaders say martech investment fails to deliver ROI...

DARMSTADT, Germany--(BUSINESS WIRE)--Focused Energy, the world’s leading laser fusion company, has raised $240 million in a Series A financing round, making it the largest fully secured Series A financing in the global fusion industry to date. In addition to RWE, the investors include the Federal Agency for Breakthrough Innovation SPRIND, the European Innovation Council Fund, and the previous lead investor, Prime Movers Lab. The new capital is to be invested into the former RWE power plant site...

LONDON--(BUSINESS WIRE)--  FORM 8.3 IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORMATION (a) Full name of discloser Marathon Asset Management Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a) The naming of nominee or vehicle companies is insufficient. For a trust, the...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Marathon Asset Management Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must...

SHANGHAI--(BUSINESS WIRE)--China Eastern Airlines (CEAir) ha ulteriormente potenziato il proprio servizio intermodale aereo-ferroviario, integrando direttamente le opzioni di volo e di treno ad alta velocità nel processo di prenotazione dei biglietti. In questo modo, i passeggeri possono ottenere un unico biglietto valido sia per la tratta aerea sia per quella ferroviaria ad alta velocità, vivendo un’esperienza di viaggio più comoda, efficiente e conveniente. Basato su un’esperienza di prenotaz...

MILTON KEYNES, UK--(BUSINESS WIRE)--Teletrac Navman, a connected mobility platform, has added a new Electronic Braking Performance Monitoring System (EBPMS) to its portfolio of automated compliance products, providing a regulatory-approved output that saves fleets time and protects operator licenses. The integrated reporting available through the EBPMS is strictly aligned with the Drivers and Vehicle Standards Agency’s (DVSA) industry specification. It ensures braking performance is captured wi...

SHANGHAI--(BUSINESS WIRE)--China Eastern Airlines (CEAir) has further upgraded its air-rail intermodal service by integrating flight and high-speed rail options directly into the ticket booking process, enabling passengers to obtain a single ticket covering both air and high-speed rail segments for a more convenient, efficient, and cost-effective travel experience. Featuring an artificial intelligence (AI)-powered seamless ticket booking experience, the integrated air-rail service is jointly de...

LONDON--(BUSINESS WIRE)--Combat Medical (Combat), a medical device company optimising the delivery and efficacy of cancer therapeutics, today announced an update on its HIVEC® HEAT FDA registration trial at The American Urological Association (AUA) Annual Meeting. Underscoring the potential of the study to expand bladder-preserving treatment options for cancer patients, Professor Leyshon Griffiths, the trial’s Chief Investigator, provided an update, outlining the study design and recruitment pr...

中國北京--(BUSINESS WIRE)--(美國商業資訊)-- 百奧賽圖（北京）醫藥科技股份有限公司（以下簡稱「百奧賽圖」，SSE: 688796；HKEX: 02315）近日宣布正式發表RenSuper Workstation，這一AI驅動的下一代抗體發現平台針對全球合作夥伴提供可現貨取得的大規模、經實驗驗證的全人源治療性抗體資源，支援推動抗體發現從「客製化專案」邁向「可檢索、可規模化、更高效」的新模式。 平台崛起的基石：真實全人抗體庫 + AI與自動化雙引擎 RenSuper Workstation的核心基礎，來自百奧賽圖憑藉自主RenMice®全人抗體小鼠平台長期累積的規模化免疫與真實資料體系。 圍繞1000多個潛在可成藥標靶，百奧賽圖展開大規模體內免疫與篩選，建構了海量真實全人抗體序列「現貨分子庫」。這一「真實庫」與傳統依賴預測模型生成的虛擬庫不同，其每條序列均來源於體內免疫並經過實驗驗證，具備真實結合與功能證據，為抗體研發提供更可靠的源頭分子資產。 在此基礎上，RenSuper將大規模體內免疫、下一代定序（NGS）、AI驅動的高通量篩選、實驗驗證整合為統一作業流程，並結合...